Aspergillosis
MONDO:0005657Aspergillosis is an infection, growth, or allergic response caused by the Aspergillus fungus. There are several different kinds of aspergillosis. One kind is allergic bronchopulmonary aspergillosis (also called ABPA), a condition where the fungus causes allergic respiratory symptoms similar to asthma, such as wheezing and coughing, but does not actually invade and destroy tissue. Another kind of aspergillosis is invasive aspergillosis. This infection usually affects people with weakened immune systems due to cancer, AIDS, leukemia, organ transplantation, chemotherapy, or other conditions or events that reduce the number of normal white blood cells. In this condition, the fungus invades and damages tissues in the body. Invasive aspergillosis most commonly affects the lungs, but can also cause infection in many other organs and can spread throughout the body (commonly affecting the kidneys and brain). Aspergilloma, a growth (fungus ball) that develops in an area of previous lung disease such as tuberculosis or lung abscess, is a third kind of aspergillosis. This type of aspergillosis is composed of a tangled mass of fungus fibers, blood clots, and white blood cells. The fungus ball gradually enlarges, destroying lung tissue in the process, but usually does not spread to other areas.
57 clinical trials for this condition and its sub-types, 20 tagged with Aspergillosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Aspergillosis
-
Pulmonary aspergilloma 11 trials · 38 incl. sub-types
2 sub-types
- Invasive aspergillosis 31 trials
- Malt worker's lung 0 trials
-
Allergic bronchopulmonary aspergillosis 15 trials
1 sub-type
- Malt worker's lung 0 trials
-
Neuroaspergillosis 1 trial
-
Aspergillus niger infection 0 trials
-
New inhaled antifungal shows promise for lung transplant patients
Disease control CompletedThis study tested a new drug called opelconazole, given as a mist through a nebulizer, to prevent a serious fungal lung infection (aspergillosis) in people who had a lung transplant. The trial involved 102 participants and compared the drug to standard care. The main goal was to …
Phase 2 • Sponsor: Pulmocide Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Cresemba under the microscope: Real-World safety check for fungal infections
Disease control CompletedThis study looked at how safe and effective the drug Cresemba (isavuconazole) is for Korean patients with serious fungal infections like invasive aspergillosis or mucormycosis. Researchers tracked side effects and how well the drug worked in 94 adults. The goal was to confirm the…
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
A radioactive 'Iron Magnet' could reveal hidden lung fungus
Diagnosis CompletedThis trial tests whether a new imaging tracer, gallium-68-deferoxamine, can make Aspergillus fungus infections in the lungs visible on a PET/CT scan. The study involves 10 adults with suspected chronic pulmonary aspergillosis or allergic bronchopulmonary aspergillosis. The goal i…
Phase 2 • Sponsor: Radboud University Medical Center • Aim: Diagnosis
Last updated Aug 20, 2026 00:00 UTC
-
New DNA test could speed up fungal infection diagnosis in cancer patients
Diagnosis CompletedThis study tested a new DNA test called the MycoGenie kit to see how well it can diagnose invasive aspergillosis, a serious fungal infection, in 350 blood cancer patients. The test looks for the fungus's DNA in blood samples and can also detect drug resistance. The goal is to fin…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Diagnosis
Last updated Jun 27, 2026 07:58 UTC
-
Did pandemic precautions lower fungal infections? hospital records hold clues
Knowledge-focused CompletedResearchers reviewed hospital records from 1,441 patients to compare fungal infection rates during the SARS-CoV-2 pandemic and afterward. They calculated positivity rates for Candida and Aspergillus species and other fungi. The study examines whether infection control measures ch…
Sponsor: Bekir Sami Uyanık • Aim: Knowledge-focused
Last updated Sep 21, 2026 18:00 UTC
-
Hidden danger: flu patients in ICU face fungal lung threat
Knowledge-focused CompletedThis study tracked 241 ICU patients with severe influenza to see how many developed a fungal lung infection called IAPA. Researchers collected blood and fluid samples to identify risk factors. The goal is to help doctors spot high-risk patients earlier.
Sponsor: Radboud University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Hidden fungal threat in COVID-19 ICU patients revealed
Knowledge-focused CompletedThis study monitored 219 adults with severe COVID-19 who needed a ventilator for at least 72 hours. Researchers checked for serious fungal infections, especially aspergillosis, using standard diagnostic methods. The goal was to learn how common these infections are and what puts …
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:12 UTC
-
New study aims to perfect antifungal dosing for sickest ICU patients
Knowledge-focused CompletedThis study looked at 32 adults in the ICU on ECMO life support who had severe influenza or COVID-19 and a serious fungal lung infection called aspergillosis. Researchers measured how the antifungal drug voriconazole behaves in the body to find the best dose for these very ill pat…
Sponsor: University Hospitals, Leicester • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
New scan method could improve fungal infection care in cancer patients
Knowledge-focused CompletedThis study looked at whether a special type of scan (PET/CT) can help doctors see if treatment for a serious fungal lung infection is working earlier than usual. It involved 51 adults with blood cancer and invasive pulmonary aspergillosis. The goal was to see if the scan results …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC